| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 990K | 13.75M | 9.19M | 30.98M | 15.62M | 9.16M | 3.5M |
| Revenue Growth % | - | 12.89% | -0.33% | 2.37% | -0.5% | -0.41% | -0.62% |
| Cost of Goods Sold | 38.99M | 24.94M | 44.85M | 47.11M | 64.32M | 1.02M | 0 |
| COGS % of Revenue | 39.38% | 1.81% | 4.88% | 1.52% | 4.12% | 0.11% | - |
| Gross Profit | -38M | -11.19M | -35.65M | -16.12M | -48.7M | 8.14M | 3.5M |
| Gross Margin % | -38.38% | -0.81% | -3.88% | -0.52% | -3.12% | 0.89% | 1% |
| Gross Profit Growth % | - | 0.71% | -2.19% | 0.55% | -2.02% | 1.17% | -0.57% |
| Operating Expenses | 41.46M | 7.31M | 8.87M | 18.02M | 22.2M | 83.56M | 40.5M |
| OpEx % of Revenue | 41.88% | 0.53% | 0.96% | 0.58% | 1.42% | 9.12% | 11.57% |
| Selling, General & Admin | 2.9M | 7.31M | 8.87M | 18.02M | 22.2M | 24.93M | 8.39M |
| SG&A % of Revenue | 2.93% | 0.53% | 0.96% | 0.58% | 1.42% | 2.72% | 2.4% |
| Research & Development | 38.56M | 24.94M | 44.85M | 47.11M | 64.32M | 59.65M | 32.11M |
| R&D % of Revenue | 38.95% | 1.81% | 4.88% | 1.52% | 4.12% | 6.51% | 9.17% |
| Other Operating Expenses | 0 | -24.94M | -44.85M | -47.11M | -64.32M | -1.02M | 0 |
| Operating Income | -40.89M | -18.49M | -44.52M | -34.14M | -70.9M | -75.42M | -37M |
| Operating Margin % | -41.31% | -1.34% | -4.84% | -1.1% | -4.54% | -8.23% | -10.57% |
| Operating Income Growth % | - | 0.55% | -1.41% | 0.23% | -1.08% | -0.06% | 0.51% |
| EBITDA | -40.47M | -18.25M | -44.22M | -33.59M | -70.15M | -74.4M | -35.47M |
| EBITDA Margin % | -40.88% | -1.33% | -4.81% | -1.08% | -4.49% | -8.12% | -10.14% |
| EBITDA Growth % | - | 0.55% | -1.42% | 0.24% | -1.09% | -0.06% | 0.52% |
| D&A (Non-Cash Add-back) | 422K | 243K | 300K | 544K | 751K | 1.02M | 1.53M |
| EBIT | -40.87M | -18.49M | -44.52M | -34.14M | -70.9M | -75.42M | -37M |
| Net Interest Income | 0 | 0 | 0 | 23K | 2.15M | 7.11M | 7.37M |
| Interest Income | 0 | 0 | 0 | 23K | 2.15M | 7.11M | 7.37M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 29K | 1.68M | 263K | 23K | 2.14M | 7.09M | 445K |
| Pretax Income | -40.87M | -16.82M | -44.26M | -34.12M | -68.77M | -68.33M | -36.55M |
| Pretax Margin % | -41.28% | -1.22% | -4.81% | -1.1% | -4.4% | -7.46% | -10.44% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -162K | 13K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -40.87M | -16.82M | -44.26M | -34.12M | -68.77M | -68.17M | -36.57M |
| Net Margin % | -41.28% | -1.22% | -4.81% | -1.1% | -4.4% | -7.44% | -10.45% |
| Net Income Growth % | - | 0.59% | -1.63% | 0.23% | -1.02% | 0.01% | 0.46% |
| Net Income (Continuing) | -40.87M | -16.82M | -44.26M | -34.12M | -68.77M | -68.17M | -36.57M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.14 | -0.47 | -3.16 | -0.95 | -1.90 | -1.63 | -1.02 |
| EPS Growth % | - | 0.59% | -5.72% | 0.7% | -1% | 0.14% | 0.37% |
| EPS (Basic) | -1.14 | -0.47 | -3.16 | -0.95 | -1.90 | -1.63 | -1.02 |
| Diluted Shares Outstanding | 35.85M | 35.85M | 13.99M | 35.98M | 36.19M | 41.74M | 48.26M |
| Basic Shares Outstanding | 35.85M | 35.85M | 13.99M | 35.98M | 36.19M | 41.74M | 48.26M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 19.98M | 85.2M | 165.97M | 236.52M | 160.01M | 178.66M | 127.17M |
| Cash & Short-Term Investments | 18.16M | 82.08M | 162.49M | 232.22M | 156.95M | 175.47M | 124.39M |
| Cash Only | 18.16M | 82.08M | 162.49M | 232.22M | 59.92M | 119.89M | 39.39M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 97.03M | 55.57M | 84.99M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 582K | 1.27M | 1.54M | 629K | 964K | 1.15M | 2.78M |
| Total Non-Current Assets | 696K | 769K | 2.44M | 11.36M | 12.25M | 13.43M | 14.34M |
| Property, Plant & Equipment | 696K | 769K | 1.56M | 8.98M | 8.46M | 8.02M | 4.23M |
| Fixed Asset Turnover | 1.42x | 17.88x | 5.88x | 3.45x | 1.85x | 1.14x | 0.83x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 872K | 2.39M | 3.79M | 5.41M | 10.11M |
| Total Assets | 20.68M | 85.97M | 168.4M | 247.88M | 172.26M | 192.09M | 141.51M |
| Asset Turnover | 0.05x | 0.16x | 0.05x | 0.13x | 0.09x | 0.05x | 0.02x |
| Asset Growth % | - | 3.16% | 0.96% | 0.47% | -0.31% | 0.12% | -0.26% |
| Total Current Liabilities | 3.82M | 24.3M | 28.33M | 27.19M | 21.5M | 14.21M | 10.78M |
| Accounts Payable | 2.27M | 935K | 2.12M | 2.38M | 2.09M | 2.07M | 897K |
| Days Payables Outstanding | 21.22 | 13.68 | 17.27 | 18.47 | 11.88 | 739.3 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 126K | 1000K | 1000K | 1000K | 1000K | 0 | 0 |
| Other Current Liabilities | 126K | 1.16M | 2.2M | 2.83M | 5.11M | 3.4M | 1.75M |
| Current Ratio | 5.22x | 3.51x | 5.86x | 8.70x | 7.44x | 12.58x | 11.80x |
| Quick Ratio | 5.22x | 3.51x | 5.86x | 8.70x | 7.44x | 12.58x | 11.80x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 62.69M | 123.14M | 241.12M | 12.81M | 3.79M | 8.13M | 4.8M |
| Long-Term Debt | 62.58M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 5.13M | 3.79M | 7.18M | 3.74M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 78.87M | 205.98M | 0 | 0 | 950K | 1.06M |
| Total Liabilities | 66.52M | 147.44M | 269.45M | 40M | 25.29M | 22.34M | 15.58M |
| Total Debt | 62.58M | 0 | 186K | 6.99M | 5.69M | 10.74M | 7.52M |
| Net Debt | 44.42M | -82.08M | -162.31M | -225.23M | -54.23M | -109.16M | -31.87M |
| Debt / Equity | - | - | - | 0.03x | 0.04x | 0.06x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | -45.84M | -61.46M | -101.05M | 207.88M | 146.97M | 169.76M | 125.93M |
| Equity Growth % | - | -0.34% | -0.64% | 3.06% | -0.29% | 0.16% | -0.26% |
| Book Value per Share | -1.28 | -1.71 | -7.22 | 5.78 | 4.06 | 4.07 | 2.61 |
| Total Shareholders' Equity | -45.84M | -61.46M | -101.05M | 207.88M | 146.97M | 169.76M | 125.93M |
| Common Stock | 19K | 3K | 3K | 36K | 36K | 48K | 48K |
| Retained Earnings | -50.27M | -67.08M | -111.34M | -145.45M | -214.22M | -282.38M | -331.62M |
| Treasury Stock | -4.41M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | -763K | -48K | 68K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -11.61M | 47.93M | -37.83M | -60.25M | -74.11M | -79.74M | -46M |
| Operating CF Margin % | -11.73% | 3.48% | -4.11% | -1.94% | -4.75% | -8.71% | -13.14% |
| Operating CF Growth % | - | 5.13% | -1.79% | -0.59% | -0.23% | -0.08% | 0.42% |
| Net Income | -40.87M | -16.82M | -44.26M | -34.12M | -68.77M | -68.17M | -49.23M |
| Depreciation & Amortization | 422K | 243K | 300K | 544K | 751K | 1.02M | 490K |
| Stock-Based Compensation | 314K | 1.17M | 1.8M | 5.18M | 7.53M | 0 | 5.29M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 29.02M | -121K | 12.1M | 1.17M | 1.52M | 9.07M | 1.42M |
| Working Capital Changes | 58K | 63.45M | -7.77M | -33.03M | -15.14M | -21.67M | -3.98M |
| Change in Receivables | 0 | -1.33M | 519K | 361K | -291K | 0 | 0 |
| Change in Inventory | 0 | 1.33M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 602K | -1.33M | 0 | 0 | 0 | -2.87M | -1.17M |
| Cash from Investing | 10.97M | -316K | 2.92M | -1.76M | -99.28M | 64.14M | -34.9M |
| Capital Expenditures | -305K | -316K | -766K | -1.76M | -1.43M | -414K | 0 |
| CapEx % of Revenue | 0.31% | 0.02% | 0.08% | 0.06% | 0.09% | 0.05% | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 11.27M | 0 | 0 | 0 | 0 | 0 | -7.07M |
| Cash from Financing | 0 | 16.32M | 116.18M | 131.74M | 1.09M | 75.98M | 0 |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 25K | 70K | 582K | 1.09M | 39.09M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -11.91M | 47.61M | -38.59M | -62.01M | -75.54M | -80.16M | -46M |
| FCF Margin % | -12.03% | 3.46% | -4.2% | -2% | -4.84% | -8.75% | -13.14% |
| FCF Growth % | - | 5% | -1.81% | -0.61% | -0.22% | -0.06% | 0.43% |
| FCF per Share | -0.33 | 1.33 | -2.76 | -1.72 | -2.09 | -1.92 | -0.95 |
| FCF Conversion (FCF/Net Income) | 0.28x | -2.85x | 0.85x | 1.77x | 1.08x | 1.17x | 1.26x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -63.87% | -38.76% | -43.04% | -24.73% |
| Return on Invested Capital (ROIC) | - | - | - | - | -141.07% | -73.77% | -35.88% |
| Gross Margin | -3837.98% | -81.33% | -387.79% | -52.03% | -311.84% | 88.86% | 100% |
| Net Margin | -4127.78% | -122.28% | -481.36% | -110.1% | -440.29% | -744.17% | -1044.8% |
| Debt / Equity | - | - | - | 0.03x | 0.04x | 0.06x | 0.06x |
| FCF Conversion | 0.28x | -2.85x | 0.85x | 1.77x | 1.08x | 1.17x | 1.26x |
| Revenue Growth | - | 1289.19% | -33.15% | 237.01% | -49.59% | -41.35% | -61.79% |
ImageneBio Inc (IMA) reported $3.5M in revenue for fiscal year 2024. This represents a 254% increase from $1.0M in 2018.
ImageneBio Inc (IMA) saw revenue decline by 61.8% over the past year.
ImageneBio Inc (IMA) reported a net loss of $45.3M for fiscal year 2024.
ImageneBio Inc (IMA) has a return on equity (ROE) of -24.7%. Negative ROE indicates the company is unprofitable.
ImageneBio Inc (IMA) had negative free cash flow of $46.9M in fiscal year 2024, likely due to heavy capital investments.